Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of TAK-438
Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: TAK-438, esomeprazole (Drug); Esomeprazole, TAK-438 (Drug); TAK-438, rabeprazole sodium (Drug); Rabeprazole sodium, TAK-438 (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Takeda Official(s) and/or principal investigator(s): General Manager, Study Director, Affiliation: Takeda
Summary
The purpose of this study is to investigate the acid-inhibitory effect of multiple oral
doses of TAK-438 and the relative effect of TAK-438 versus two controls (esomeprazole and
rabeprazole sodium) in healthy Japanese adult male participants with the CYP2C19 EM
genotype.
Clinical Details
Official title: Phase 3 Open-Label Crossover Pharamacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Intragastric pH time course over 24 hours
Secondary outcome: Frequency of adverse eventsChange in Vital signs 12-lead electrocardiogram (at rest) Number of participants with markedly abnormal laboratory values
Detailed description:
This is a Phase 3 open-label crossover study to evaluate the acid-inhibitory effect
following 7 days multiple doses of TAK-438 (20 mg per dose) and esomeprazole (20 mg per
dose) (Cohort 1) or TAK-438 (20 mg per dose) and rabeprazole sodium (10 mg per dose) (Cohort
2) in healthy Japanese adult male participants (CYP2C19 genotype: EM). There will be a
total of 20 subjects, 5 per group for both Cohorts 1 and 2. At least 2 subjects each with
the homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will be enrolled among the
5 subjects per group.
The drug being tested in this study is called TAK-438. This study will look at the acid
inhibitory effect following 7 days multiple doses of TAK-438 and esomeprazole (Cohort 1) or
TAK-438 and rabeprazole sodium (Cohort 2) in healthy Japanese adult male participants witrh
the CYP2C19 EM genotype.
The study will enroll a total of 20 participants, 5 per group for both Cohorts. At least 2
subjects each with the homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will be
enrolled among the 5 subjects per group.
- Group A, Cohort 1: TAK-438 (20 mg per dose for 7 days) followed by esomeprazole (20 mg
per dose for 7 days)
- Group B, Cohort 1: esomeprazole (20 mg per dose for 7 days) followed by TAK-438 (20 mg
per dose for 7 days)
- Group C, Cohort 2: TAK-438 (20 mg per dose for 7 days) followed by rabeprazole sodium
(10 mg per dose for 7 days)
- Group D, Cohort 2: rabeprazole sodium (10 mg per dose for 7 days) followed by TAK-438
(20 mg per dose for 7 days).
All participants will be asked to take Study Medication at the same time each day throughout
the study. This single center trial will be conducted in Japan. The overall time to
participate in this study is 31 days.
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- 1. Is a healthy Japanese adult male volunteer 2. Is aged 20 to 45 years, inclusive,
at the time of informed consent. 3. Has been confirmed at CYP2C19 genotyping as an
Extensive Metabolizer [EM (*1/*1,*1/*2,*1/*3)] .
4. Capable of understanding and complying with the protocol requirements. 5. The
participant signs and dates a written informed consent form prior to the initiation
of any study procedures.
6. Weighs 50 kg or more and has BMI of 18. 5 or more and less than 25. 0 kg/m2 at
Screening or admission (Day - 3).
7. H. pylori-negative at Screening.
Exclusion Criteria:
- Has undergone resection of the upper gastrointestinal tract or vagotomy. 2. Was
determined to have hypoacidity or anacidity 3. Has a present or past history of
acid-related disease (reflux esophagitis, gastric ulcer, duodenal ulcer, non-erosive
gastroesophageal reflux, Barrett's esophagus, Zollinger-Ellison syndrome, etc.) 4.
Has undergone eradication of H. pylori within 6 months prior to the start of the
study drug administration.
5. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other
abnormalities which may impact the ability of the subject to participate or
potentially confound the study results.
6. Has a known hypersensitivities or allergies to drugs or food. 7. Has a history of
drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5
years prior to the start of the study drug administration.
8. Has poor peripheral venous access. 9. Had 200 mL or more of whole blood drawn
within 4 weeks (28 days) prior to the start of the study drug administration or 400
mL or more of whole blood drawn within 12 weeks (84 days) prior to the start of the
study drug administration.
10. Had a total volume of 800 mL or more of whole blood drawn within 52 weeks (364
days) prior to the start of the study drug administration.
11. Has undergone blood component draw within 2 weeks (14 days) prior to the start of
the study drug administration.
12. Requires treatment with any of the excluded medications specified in the study or
requires nutrition with any vitamin supplements or foods prohibited in the study.
13. Has received study medication within 16 weeks (112 days) prior to the start of
the study drug administration.
14. Has received TAK-438 in the past. 15. Has a history of cancer. 16. Has a
positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV)
antibody, human immunodeficiency virus (HIV) antibody/antigen or serological reaction
for syphilis at Screening.
17. Has a Screening or admission (Day - 3) abnormal clinically significant ECG. 18.
Has abnormal Screening or admission (Day - 3) laboratory values that suggest a
clinically significant underlying disease or subject with the following lab
abnormalities: ALT or AST > twice the upper limited of the normal range.
19. Is an immediate family member, study site employee, or in a dependent
relationship with a study site employee who is involved in the conduct of this study
(e. g., spouse, parent, child, sibling) or may consent under duress.
20. Participant who, in the opinion of the investigator or sub-investigator, is
unlikely to comply with the protocol or is unsuitable for any other reasons.
Locations and Contacts
Fukuoka-shi, Fukuoka, Japan
Additional Information
Starting date: January 2014
Last updated: August 7, 2014
|